Heron Therapeutics Inc.

17.87+0.1400+0.79%Vol 1.00M1Y Perf 26.59%
Apr 16th, 2021 16:00 DELAYED
BID17.71 ASK17.90
Open17.80 Previous Close17.73
Pre-Market- After-Market17.87
 - -  - -%
Target Price
34.57 
Analyst Rating
Strong Buy 1.10
Potential %
93.45 
Finscreener Ranking
★★★★     54.19
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     49.02
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★     61.40
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap1.63B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
54.15 
Earnings Date
5th May 2021

Today's Price Range

17.5117.99

52W Range

12.5222.40

5 Year PE Ratio Range

-6.30-4.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
7.65%
1 Month
9.10%
3 Months
1.30%
6 Months
17.26%
1 Year
26.59%
3 Years
-42.17%
5 Years
-14.54%
10 Years
670.26%

TickerPriceChg.Chg.%
HRTX17.870.14000.79
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.40
3.10
0.06
0.10
-118.60
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
59.20
-212.20
-209.60
-2 961.40
-
RevenueValueIndustryS&P 500US Markets
63.24M
0.69
36.61
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.68-0.680.00
Q03 2020-0.65-0.641.54
Q02 2020-0.59-0.61-3.39
Q01 2020-0.63-0.579.52
Q04 2019-0.58-0.65-12.07
Q03 2019-0.60-0.4230.00
Q02 2019-0.68-0.637.35
Q01 2019-0.47-0.80-70.21
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.5721.92Positive
6/2021 QR-0.5611.11Positive
12/2021 FY-2.12-7.61Negative
12/2022 FY-1.25-111.86Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.57
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.00M
Shares Outstanding91.40M
Trades Count9.02K
Dollar Volume45.51M
Avg. Volume1.01M
Avg. Weekly Volume815.90K
Avg. Monthly Volume1.13M
Avg. Quarterly Volume1.01M

Heron Therapeutics Inc. (NASDAQ: HRTX) stock closed at 17.87 per share at the end of the most recent trading day (a 0.79% change compared to the prior day closing price) with a volume of 1.00M shares and market capitalization of 1.63B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 223 people. Heron Therapeutics Inc. CEO is Barry D. Quart.

The one-year performance of Heron Therapeutics Inc. stock is 26.59%, while year-to-date (YTD) performance is -15.59%. HRTX stock has a five-year performance of -14.54%. Its 52-week range is between 12.52 and 22.4, which gives HRTX stock a 52-week price range ratio of 54.15%

Heron Therapeutics Inc. currently has a PE ratio of -6.90, a price-to-book (PB) ratio of 6.67, a price-to-sale (PS) ratio of 23.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.85%, a ROC of -73.66% and a ROE of -67.23%. The company’s profit margin is -%, its EBITDA margin is -209.60%, and its revenue ttm is $63.24 Million , which makes it $0.69 revenue per share.

Of the last four earnings reports from Heron Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Heron Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Heron Therapeutics Inc. is Strong Buy (1.1), with a target price of $34.57, which is +93.45% compared to the current price. The earnings rating for Heron Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Heron Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Heron Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.31, ATR14 : 0.93, CCI20 : 127.12, Chaikin Money Flow : 0.06, MACD : -0.36, Money Flow Index : 73.38, ROC : 16.80, RSI : 54.43, STOCH (14,3) : 96.21, STOCH RSI : 1.00, UO : 61.30, Williams %R : -3.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Heron Therapeutics Inc. in the last 12-months were: Barry D. Quart (Option Excercise at a value of $0), David Szekeres (Option Excercise at a value of $0), David Szekeres (Sold 4 398 shares of value $85 180 ), John W. Poyhonen (Option Excercise at a value of $0), Kimberly J. Manhard (Option Excercise at a value of $130 000), Kimberly J. Manhard (Sold 12 316 shares of value $232 352 ), Lisa Peraza (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
1 (10.00 %)
1 (11.11 %)
1 (11.11 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.11
Strong Buy
1.11

Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.

CEO: Barry D. Quart

Telephone: +1 858 251-4400

Address: 4242 Campus Point Court, San Diego 92121, CA, US

Number of employees: 223

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

42%58%

Bearish Bullish

55%45%

News

Stocktwits